Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Gene and Cell Therapy: Shaping the Future of Medicine

August 26th 2024

Marco Davila, MD, PhD, discusses how to shape the future of medicine with gene and cell therapy.

PARP Inhibitors and ADCs Spark Change Across Ovarian and Cervical Cancer Paradigms

August 26th 2024

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Erdafitinib Wins EU Approval for FGFR3+ Unresectable, Metastatic Urothelial Carcinoma

August 23rd 2024

Erdafitinib was approved by the European Commission for pretreated unresectable or metastatic urothelial carcinoma harboring FGFR3 alterations.

DSP-5336 Is Safe, Generates Responses in KMT2A+ or NPM1+ R/R AML

August 22nd 2024

Naval G. Daver, MD, discusses efficacy and safety data from the first-in-human phase 1/2 study investigating DSP-5336 for relapsed or refractory acute leukemia.

The HR-Positive Breast Cancer Treatment Paradigm Sits on the Cusp of Significant Shifts

August 22nd 2024

Shipra Gandhi, MD, highlights findings with oral SERDs in HR-positive breast cancer and options to consider after progression on CDK4/6 inhibitors.

Fulzerasib Approved in China for KRAS G12C–Mutant Advanced NSCLC

August 22nd 2024

China’s National Medical Products Administration has approved fulzerasib for the treatment of adult patients with advanced KRAS G12C–mutant NSCLC.

From Bench to Bedside: HIF-2α Inhibition in RCC

August 22nd 2024

In 2024, kidney cancer is projected to be one of the top 10 cancers in terms of incidence rate in the United States, with an estimated 81,610 new diagnoses.

PRECISION 1 Trial to End After Nab-Sirolimus is Projected to Miss Efficacy Threshold in TSC1/2+ Solid Tumors

August 21st 2024

Aadi Bioscience will end the PRECISION 1 trial evaluating nab-sirolimus in solid tumors harboring TSC1/2 alterations.

Repotrectinib Adds to the Treatment Armamentarium for NTRK+ Advanced Solid Tumors

August 21st 2024

Luis E. Raez, MD, FACP, FCCP, FASCO, discusses the FDA approval of repotrectinib for NTRK-positive advanced solid tumors.

FDA Approves First-Line Amivantamab Plus Lazertinib for EGFR+ Advanced NSCLC

August 20th 2024

The FDA has approved first-line amivantamab plus lazertinib for locally advanced or metastatic EGFR-mutated non–small cell lung cancer.

Tumor-Killing Technology in Head and Neck Cancer

August 19th 2024

Noah Kalman, MD, MBA, details new technology for treating head and neck cancer, and ongoing trials examining therapies at Miami Cancer Institute.

Linvoseltamab Demonstrates Deep, Durable Responses in R/R Myeloma Ahead of FDA Action Date

August 15th 2024

Suzanne Lentzsch, MD, PhD, discusses updated data from the LINKER-MM1 study of linvoseltamab in relapsed/refractory multiple myeloma.

The Noninvasive Biomarker KIM-1 Is Front and Center in RCC Investigations

August 15th 2024

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

FDA Grants Fast Track Status to AC699 for ER+/HER2–, ESR1-Mutated Breast Cancer

August 14th 2024

AC699 has won fast track designation from the FDA for select patients with ER-positive, HER2-negative, ESR1-mutated breast cancer.

Analyzing the “RAS Pie” for Methods to Target Mutations in GI Cancers

August 14th 2024

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.

Vebreltinib Induces Responses in non-CNS MET Fusion+ Solid Tumors

August 13th 2024

Vebreltinib demonstrated preliminary activity in patients with non–central nervous system solid tumors harboring MET fusions.

Small Clones, Outsized Consequences: The Many Faces of Clonal Hematopoiesis

August 13th 2024

Danielle E. Hammond, MD, FRCP(C), of The University of Texas MD Anderson Cancer Center, discusses the many faces of clonal hematopoiesis.

Review Highlights the Need to Increase Germline BRCA Mutation Testing in Males

August 12th 2024

Kara N. Maxwell, MD, PhD, discusses the need to improve genetic testing rates for BRCA mutations in the male population.

Olomorasib Plus Pembrolizumab Generates Antitumor Activity in KRAS G12C+ NSCLC

August 8th 2024

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

Paramountcy of Molecular Testing Is Increasing in Early-Stage NSCLC

August 7th 2024

Fred R. Hirsch, MD, PhD, discusses the role of molecular testing in non–small cell lung cancer.